<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Betaine (anhydrous, not equivalent to betaine hydrochloride): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Betaine (anhydrous, not equivalent to betaine hydrochloride): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Betaine (anhydrous, not equivalent to betaine hydrochloride): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8598" href="/d/html/8598.html" rel="external">see "Betaine (anhydrous, not equivalent to betaine hydrochloride): Drug information"</a> and <a class="drug drug_patient" data-topicid="11588" href="/d/html/11588.html" rel="external">see "Betaine (anhydrous, not equivalent to betaine hydrochloride): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F140590"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cystadane</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056826"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Homocystinuria, Treatment Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462380"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26de6b4a-249a-4081-84f6-ed040dd5b30b">Homocystinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homocystinuria</b>: <b>Note: </b>The overall role of betaine in management of homocystinuria and effectiveness is variable and dependent upon several factors, including specific enzyme deficiency, genetic mutation(s), and clinical condition; dose should be individualized.</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonate: Oral: 50 mg/kg/dose twice daily; increase at weekly intervals in 50 mg/kg/day increments; increase gradually until plasma total homocysteine is undetectable or present in small amounts (Al Tawari 2002; Diekman 2014; Schiff 2011). <b>Note:</b> Minimal additional benefit expected with doses &gt;150 to 200 mg/kg/day or exceeding a twice daily dosing schedule (Morris 2017); however, case reports in infants suggest more frequent dosing may be necessary in some patients (Schiff 2011; Ucar 2010).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F140596"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26de6b4a-249a-4081-84f6-ed040dd5b30b">Homocystinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homocystinuria:</b>
<b>Note: </b>The overall role of betaine in management of homocystinuria and effectiveness is variable and dependent upon several factors, including specific enzyme deficiency, genetic mutation(s), and clinical condition; dose should be individualized.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;3 years: Oral: 50 mg/kg/dose twice daily; increase at weekly intervals in 50 mg/kg/day increments until plasma total homocysteine is undetectable or present in small amounts. <b>Note:</b> Minimal additional benefit has been observed with dosages &gt;150 to 200 mg/kg/day or exceeding a twice daily dosing schedule (Morris 2017); however, case reports in infants suggest more frequent dosing may be necessary in some patients (Schiff 2011; Ucar 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Oral: 3,000 mg twice daily; increase gradually until plasma total homocysteine is undetectable or present in small amounts; in some patients, doses up to 20 g/day have been needed to control homocysteine plasma concentrations. <b>Note:</b> Minimal benefit has been observed with dosages &gt;20 g/day or exceeding a twice daily dosing schedule.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090219"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090220"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F140592"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8598" href="/d/html/8598.html" rel="external">see "Betaine (anhydrous, not equivalent to betaine hydrochloride): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26de6b4a-249a-4081-84f6-ed040dd5b30b">Homocystinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homocystinuria:</b>
<b>Oral:</b> 3 g twice daily. Dosages of up to 20 g/day have been necessary to control homocysteine levels in some patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosage in all patients can be gradually increased until plasma total homocysteine is undetectable or present only in small amounts. One in vitro study indicated minimal benefit from exceeding a twice daily dosing schedule and a 150 mg/kg/day dosage.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990966"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988334"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F140575"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Abnormal skin odor</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, dysgeusia, gastrointestinal distress, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychological disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, glossitis, stomach discomfort, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, brain edema (associated with hypermethioninemia) depression, irritability, personality disorder, sleep disorder</p></div>
<div class="block coi drugH1Div" id="F140584"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F2989268"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cystathionine beta-synthase (CBS) deficiency: Use caution in patients with CBS deficiency; treatment with betaine may cause large increases of plasma methionine concentrations which may cause cerebral edema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>﻿Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Betaine anhydrous, a prescription medication indicated for the treatment of homocystinuria and betaine hydrochloride, a nutritional supplement, are not to be used interchangeably (ISMP 2016).</p></div>
<div class="block foc drugH1Div" id="F140580"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Oral, as anhydrous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cystadane: 1 g/scoop (180 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/scoop (180 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p></div>
<div class="block geq drugH1Div" id="F140570"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adip drugH1Div" id="F53565522"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, and folate have been helpful in the management of homocystinuria and are often used in conjunction.</p></div>
<div class="block accres drugH1Div" id="F11239625"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Ordering information is available at https://www.cystadane.com/physicians/prescribing-cystadane/.</p></div>
<div class="block admp drugH1Div" id="F52612302"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food immediately after reconstitution; do not use if powder does not completely dissolve or gives a colored solution.</p></div>
<div class="block adm drugH1Div" id="F140582"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For oral administration. Administer without regard to food immediately after reconstitution.</p></div>
<div class="block sts drugH1Div" id="F2613425"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from moisture</p></div>
<div class="block usep drugH1Div" id="F53565648"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of homocystinuria to reduce elevated homocysteine blood concentrations (FDA approved in pediatric patients [age not specified] and adults); homocystinuria includes deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl)</p></div>
<div class="block mst drugH1Div" id="F140604"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Betaine anhydrous may be confused with betaine hydrochloride (a nutritional supplement)</p>
<p style="text-indent:-2em;margin-left:4em;">Betaine may be confused with Betadine</p>
<p style="text-indent:-2em;margin-left:4em;">Cystadane may be confused with cysteamine, cysteine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298857"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218393"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block dic drugH1Div" id="F3342811"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be mixed with water, juice, milk, formula, or with food. Betaine is a metabolite of choline and is present in small amounts in foods such as beets, spinach, cereals, and seafood.</p></div>
<div class="block pri drugH1Div" id="F140587"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The risk of adverse pregnancy outcomes may be increased in females with untreated homocystinuria (Langendonk 2012; Levin 2016; Levy 2002). Although betaine is an endogenous substance, information related to the use of betaine supplementation for treating homocystinuria in pregnancy is limited (Langendonk 2012; Levy 2002; Liu 2015; Pierre 2006; Stabler 2017; Vilaseca 2004; Wilcken 1997; Yap 2001). In general, females with inherited metabolic disease should achieve adequate metabolic control prior to conception (Langendonk 2012).</p></div>
<div class="block mopp drugH1Div" id="F53565644"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Variable based upon enzyme deficiency and genetic mutation; should include: Serum total homocysteine, methionine, and other amino acids as applicable; frequency varies based on clinical condition (Diekman 2011; Morris 2017)</p></div>
<div class="block pha drugH1Div" id="F3343058"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Betaine is an endogenous metabolite of choline. Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine. Homocystinuria is an inborn error of metabolism in which elevated plasma homocysteine levels can lead to intellectual disability, ocular abnormalities, osteoporosis, premature atherosclerosis and thromboembolic disease. Remethylation is one of the two divergent pathways in the metabolism of homocysteine. The second pathway involves transulfuration of homocysteine to produce cysteine. A number of enzymes and cofactors are also involved in these pathways.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038539"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Betaine HCL</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Acute Care ISMP Medication <i>Safety Alert</i>! http://www.ismp.org/newsletters/acutecare/issue.aspx?id=1139. Published December 1, 2016. Accessed March 8, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12142069">
<a name="12142069"></a>Al Tawari AA, Ramadan DG, Neubauer D, Heberle LC, Al Awadi F. An early onset form of methylenetetrahydrofolate reductase deficiency: a report of a family from Kuwait. <i>Brain Dev</i>. 2002;24(5):304-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/12142069/pubmed" id="12142069" target="_blank">12142069</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cystadane (betaine anhydrous) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323041">
<a name="24323041"></a>Diekman EF, de Koning TJ, Verhoeven-Duif NM, Rovers MM, van Hasselt PM. Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency. <i>JAMA Neurol</i>. 2014;71(2):188-194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/24323041/pubmed" id="24323041" target="_blank">24323041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21918856">
<a name="21918856"></a>Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. <i>J Inherit Metab Dis.</i> 2012;35(3):419-424. doi: 10.1007/s10545-011-9389-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/21918856/pubmed" id="21918856" target="_blank">21918856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27130656">
<a name="27130656"></a>Levin BL, Varga E. MTHFR: Addressing genetic counseling dilemmas using evidence-based literature. <i>J Genet Couns.</i> 2016;25(5):901-911. doi: 10.1007/s10897-016-9956-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/27130656/pubmed" id="27130656" target="_blank">27130656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12227460">
<a name="12227460"></a>Levy HL, Vargas JE, Waisbren SE. Reproductive fitness in maternal homocystinuria due to cystathionine beta-synthase deficiency. <i>J Inherit Metab Dis.</i> 2002;25(4):299-314.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/12227460/pubmed" id="12227460" target="_blank">12227460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24974159">
<a name="24974159"></a>Liu Y, Wang Q, Li X, et al. First Chinese case of successful pregnancy with combined methylmalonic aciduria and homocystinuria, cblC type. <i>Brain Dev.</i> 2015;37(3):286-291. doi: 10.1016/j.braindev.2014.06.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/24974159/pubmed" id="24974159" target="_blank">24974159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27778219">
<a name="27778219"></a>Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. <i>J Inherit Metab Dis</i>. 2017;40(1):49-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/27778219/pubmed" id="27778219" target="_blank">27778219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16972179">
<a name="16972179"></a>Pierre G, Gissen P, Chakrapani A, et al. Successful treatment of pyridoxine-unresponsive homocystinuria with betaine in pregnancy. <i>J Inherit Metab Dis.</i> 2006;29(5):688-689. doi: 10.1007/s10545-006-0352-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/16972179/pubmed" id="16972179" target="_blank">16972179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20490923">
<a name="20490923"></a>Schiff M, Benoist JF, Tilea B, Royer N, Giraudier S, Ogier de Baulny H. Isolated remethylation disorders: do our treatments benefit patients? <i>J Inherit Metab Dis</i>. 2011;34(1):137-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/20490923/pubmed" id="20490923" target="_blank">20490923</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schiff M, Benoist JF, Tilea B, Royer N, Giraudier S, Ogier de Baulny H. Erratum to: Isolated remethylation disorders: do our treatments benefit patients? <i>J Inherit Metab Dis</i>. 2011;34(6):1229.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28275971">
<a name="28275971"></a>Stabler SP, Freehauf C, Allen RH, et al. Potential misdiagnosis of hyperhomocysteinemia due to cystathionine beta-synthase deficiency during pregnancy. <i>JIMD Rep.</i> 2017;37:55-61. doi: 10.1007/8904_2017_15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/28275971/pubmed" id="28275971" target="_blank">28275971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19434424">
<a name="19434424"></a>Ucar SK, Koroğlu OA, Berk O, et al. Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency. <i>Eur J Pediatr</i>. 2010;169(2):241-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/19434424/pubmed" id="19434424" target="_blank">19434424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15617186">
<a name="15617186"></a>Vilaseca MA, Cuartero ML, Martinez de Salinas M, et al. Two successful pregnancies in pyridoxine-nonresponsive homocystinuria. <i>J Inherit Metab Dis.</i> 2004;27(6):775-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/15617186/pubmed" id="15617186" target="_blank">15617186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9211201">
<a name="9211201"></a>Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. <i>J Inherit Metab Dis.</i> 1997;20(2):295-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/9211201/pubmed" id="9211201" target="_blank">9211201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11305553">
<a name="11305553"></a>Yap S, Barry-Kinsella C, Naughten ER. Maternal pyridoxine non-responsive homocystinuria: the role of dietary treatment and anticoagulation.<i> BJOG.</i> 2001;108(4):425-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaine-anhydrous-not-equivalent-to-betaine-hydrochloride-pediatric-drug-information/abstract-text/11305553/pubmed" id="11305553" target="_blank">11305553</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13041 Version 127.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
